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Abstract 
Over the past few years, there have been calls for novel antimicrobials to combat the rise of drug-resistant bacteria. 
While some promising new discoveries have met this call, it is not nearly enough. The major problem is that although 
these new promising antimicrobials serve as a short-term solution, they lack the potential to provide a long-term 
solution. The conventional method of creating new antibiotics relies heavily on the discovery of an antimicrobial 
compound from another microbe. This paradigm of development is flawed due to the fact that microbes can easily 
transfer a resistant mechanism if faced with an environmental pressure. Furthermore, there has been some evidence 
to indicate that the environment of the microbe can provide a hint as to their virulence. Because of this, the use of 
materials with antimicrobial properties has been garnering interest. Nanoantibiotics, (nAbts), provide a new way to 
circumvent the current paradigm of antimicrobial discovery and presents a novel mechanism of attack not found in 
microbes yet; which may lead to a longer-term solution against drug-resistance formation. This allows for environ-
ment-specific activation and efficacy of the nAbts but may also open up and create new design methods for various 
applications. These nAbts provide promise, but there is still ample work to be done in their development. This review 
looks at possible ways of improving and optimizing nAbts by making them stimuli-responsive, then consider the chal-
lenges ahead, and industrial applications.
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1  Background
Since the advent of penicillin, civilization has been in a 
constant race against microbes that can often evolve in 
ways that render antimicrobials useless. Bacteria mutate 
at accelerated rates and readily transfer drug-resistant 
genes. The development of novel antimicrobials has 
fallen well behind the rate of mutation. Thus, a need for 
novel therapeutics is apparent. The scientific community 
has been taking various approaches to address the prob-
lem from discovering new drugs such as teixobactin [1] 
and its synthetic forms [2], to repurposing old antibiot-
ics through use of nanoparticles [3, 4]. Another proposed 
method of addressing the bacterial rate of drug-resistant 
formation is using RNAi and antisense technology to 
remove the silencing trait to sensitize the microbe [5–9]. 
One thing that is clear is that there is a desperate need for 
innovative therapeutics.
The problem, is that while all these new antimicrobials 
are effective and promising, they remain as only short-
term solutions to the overall challenge of drug-resistant 
microbes. It takes anywhere from of a few months to 
approximately ten years for a resistant gene to develop 
[10]. Aside from environmental pressure and overuse, 
another cause for this rapid loss of efficacy is due to the 
fact that most available antibiotics are derived from a 
compound discovered in a microbe for an example, peni-
cillin, Fig. 1. While the source microbe is resistant against 
the compound [11, 12], the unfortunate reality is that the 
resistant gene can be easily passed on through horizontal 
gene transfer [5, 11] to a target microbe. For us to truly 
gain an advantage against microbes, we need to engineer 
and design methods to avoid that cycle.
Recently, the use of nanoantibiotics as a therapeu-
tic strategy has gained a lot of attention [10, 13, 14]. 
Nanoantibiotics (nAbts) are nanomaterials that have an 
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antimicrobial activity or improve the efficacy and safety 
of antibiotics administration [10]. nAbts possess many 
advantages over conventional antibiotics, including but 
not limited to production, storage, durability, and ver-
satility. Preparation of antimicrobial nanoparticles may 
be cheaper, faster, and more adaptable with the added 
advantage of a long shelf life [10, 15]. They are typi-
cally composed of either naturally occurring antibacte-
rial substances, metals and metal oxides, carbon-based 
nanomaterials, or nanoemulsions [3, 14]. Moreover, the 
persistent misuse and overuse of current antimicrobials 
can also be attributed to the lack of patient compliance 
[16–18]. nAbts provide the added advantage of a site-
specific, sustained release that can be administered in a 
single dose. While most conventional antibiotics are a 
systematic release of therapeutics that require multiple 
doses.
The improved antimicrobial efficacy can be attributed 
to high surface area to volume ratios and unique chemi-
cal–physical properties. Some proposed antimicrobial 
mechanisms of nAbts include: (1) generation of reac-
tive oxygen species (ROS) that age bacterial intracellu-
lar components, (2) compromise the bacterial cell wall/
membrane, (3) interruption of energy transduction, 
and (4) inhibition of enzyme activity and DNA synthe-
sis [10, 15], as shown in Fig.  2. In comparison, conven-
tional antibiotic agents have treated a diverse multitude 
of microbes via interference with the integrity of the cell 
wall or membrane, hindrance DNA or RNA synthesis, 
or disruption of protein or amino acid synthesis, Fig.  2 
[5]. While there is some overlap present, such as inhibi-
tion of nucleic acid synthesis and compromising cell wall 
integrity, the mechanisms by which these occur are vastly 
different. While conventional antibiotics interfere on the 
molecular scale, nAbts physically disrupt key biological 
processes. This allows for a unique method of destroy-
ing microbes with a combination of both mechanisms. 
This review will provide an overview of various stimuli-
responsive linkers used to design a multipurpose nano-
antibiotics, the manufacturing of nAbts and the market 
potential for their production and use.
2  Different types of nanoantibiotics and the 
promise of stimuli‑response
NAbts come in different shapes and sizes, all of which 
have been continuously documented [3, 4, 10, 19, 20]. 
Briefly below, and in Table  1, is an overview of some 
of the possible category nAbts along with some brief 
examples.
2.1  Polymers
Nanoantibiotic polymers typically need to be formu-
lated into nanoparticles for full usage of the therapeutic 
antimicrobial properties. These polymers do however 
hinder the growth of bacteria through one of the nAbts 
mechanisms. While there are most likely many others 
that are not identified, examples of some well-known 
polymers are listed. Chitosan is a partially deacetylated 
chitin that has been shown to possess a wide spectrum 
of antibacterial activity [21, 22]. Chitosan’s antimicrobial 
mechanisms include increasing the permeability of the 
microbial wall or chelation trace metals [23, 24]. Gelatin 
is derived from type I collagen composed of glycine- and 
proline-rich repeating units [25–27]. Gelatin has been 
shown to damage the cell membranes of Staphylococcus 
aureus [26, 27]. An additional class of polymeric materi-
als are peptides, which have been developed as a treat-
ment against various microbes including drug-resistant 
strains [28–30]. For an example, stearylated melittin, is 
a well-known cationic antimicrobial peptide, which cre-
ates pores in the microbe membrane [31]. Furthermore, 
some synthetic and natural polymers may be considered 
as nAbts based on their abilities to act as matrices or vec-
tors for varied deliveries. An example of this is dextran or 
acetylated dextran. Though dextran has not been shown 
to demonstrate any innate antimicrobial properties, it is 
an easily modifiable polymer that can aid in antimicrobial 
therapy [32, 33].
2.2  Metals and metal oxides
Gold-based nanoparticles have been used to treat bacte-
rial infections using heat generated from photo-thermal 
effects. Gold’s antimicrobial activity is caused by strong 
Fig. 1 Current drug discovery paradigm in antibiotics. Scheme 
of the current paradigm in drug discovery. A target microbe that 
requires new antibiotics becomes the main subject of research. The 
discovery of new antimicrobial agents is usually discovered in soil or 
marine bacteria, and synthetic derivatives are generated. Based on 
current trends, these have up to 14 years of efficacy before resistance 
is developed. The resistance is usually acquired through horizontal 
gene transfer
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electrostatic attractions to the negative charge bilayer 
of the cell membrane [34, 35]. Silver, on the other hand, 
has been used since ancient times as an antimicrobial. 
Amongst all the different types of metallic nanoparticles, 
silver NPs have proven to be the most effective against 
various types of microorganisms [10]. Silver NPs work by 
interfering with the respiratory pathway and cell division. 
Additionally, the release of silver ions further enhances 
antibacterial activity [4, 10, 36]. Titanium dioxide (TiO2) 
NPs are also well known for photocatalytic antimicrobial 
activity [5, 37] as demonstrated by the strong bactericidal 
activity of TiO2 upon receiving irradiation with near-UV 
light and UV-A. TiO2 NPs work by producing ROS such 
as free hydroxyl radicals and peroxide. Finally, zinc oxide 
NPs are nontoxic and biocompatible metal oxide NPs 
that have been widely adopted throughout the biotech-
nology and consumer goods industries [3, 38]. They are 
antibacterial against some important foodborne patho-
gens [3, 10], disrupt lipids and proteins of the bacterial 
cell membrane, and promote the generation of hydrogen 
peroxide and Zn+2 ions [10].
2.3  Carbon‑derived NPs
Fullerenes—and more specifically, colloidal C60 aggre-
gates (nC60) in water—have been recently discovered to 
have beneficial antimicrobial properties [39]. Suggestions 
for the antibacterial mechanism for nC60 includes pho-
tocatalytic ROS production and lipid peroxidation in the 
cell membrane [10]. Other modifications of fullerenes 
allow for the destruction of microbes by insertion into the 
cell wall, which is then followed by the disruption of the 
cell membrane structure [3]. Additionally, single-walled 
carbon nanotubes (SWCNTs) and multi-walled carbon 
nanotubes (MWCNTs) have been used for a multitude of 
antimicrobial applications [40, 41]. CNTs destroy gram 
positive and gram negative bacteria through irradiation 
mediated oxidative stress which affects the membrane 
integrity and metabolic activity of the bacteria [3, 42].
2.4  Promise of stimuli‑response
In addition to using stimuli-responsive linkers to com-
bine conventional antibiotics and nAbts, these linkers 
are able to provide a unique advantage over current anti-
biotic strategies: they can be effectively tuned to certain 
infections or sites. To note, all organisms exist with a 
specific microenvironment around them. These environ-
ments are dynamic and deeply influenced by the organ-
isms within them. Such phenomena can be observed in 
bacterial colonies, both commensal and pathogenic [43]. 
In the case of pathogens, environmental cues usually 
determine the virulence factor. The virulence factor of 
an infection is an intrinsic trait that is usually measured 
Fig. 2 Nanoantibiotics mechanisms versus conventional antibiotic mechanism. A schematic illustration of nanoantibiotics (nAbts) mechanism in 
comparison to conventional antibiotics mechanisms. nAbts mechanisms are typically cell membrane disruption, and oxidation of cellular compo-
nents caused by reactive oxygen species (ROS); interruption of transmembrane electron transport; and mitochondria and DNA damage caused by 
heavy metal ions and ROS. Conventional antibiotics mechanism inhibits nucleic acid transcription and function caused by quinolones, fluoroqui-
nolones and rifamycins. Additionally, other conventional antibiotics can hinder protein synthesis, disrupt cell all synthesis or function, cause a loss of 
selective membrane permeability, or interfere with the synthesis of key biological components such as folic acid
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in terms of morbidity or mortality [44]. For most micro-
bial infections, these virulent factors are responsible for 
efficient multiplication in the host with such attributes 
as adherence to host tissues, production of host-specific 
toxins, invasion into host cells, and resistance to the host 
defense mechanisms. Furthermore, a large proportion of 
these virulence factors have specific environmental sig-
nals such as temperature, osmolarity, pH, oxygen, carbon 
dioxide, amino acids, and iron levels, as demonstrated 
in Fig.  3. Pathogens may use these factors as signals to 
detect their environment, for instance, cueing them as to 
whether they are in the gut versus the lung or intracel-
lular versus extracellular environments [44]. By taking 
advantage of these environmental cues, highly effective 
and multi-purpose nAbts can be created.
3  Stimuli‑responsive linkers and combinatory 
therapeutic design
It is clear that there is a synergistic opportunity in design-
ing nanoparticles with a stimuli-responsive linker. These 
stimuli can either be physical, chemical, or biological 
[45]. For this review, we will focus on stimuli responses 
that can be easily added to a nAbts system and allow for 
improved efficacy in certain environments. These stimuli 
of interests are pH, temperature, redox, enzymes, and 
light.
3.1  pH‑responsive
pH-responsive linkers have a unique advantage against 
microbes that thrive in highly acidic environments, 
whether extracellularly in the stomach (pH = 1–3) and 
gastrointestinal tract (pH = 5–8) or intracellular in the 
phagolysosomes (pH  =  4.5–5) and macrophages [45–
47]. Additionally, chronic infections and wounds have 
pH values between 5.4 and 7.4 and are another poten-
tial site for the application of this therapy [45]. Exam-
ples of microbes that thrive in an acidic environment 
include Helicobacter pylori, Agrobacterium tumefaciens 
or Vibrio cholera [45, 46]. This specificity allows for a 
direct exploitation of the stimuli-response in certain tis-
sues or in a cellular compartment. The key element for 
pH-responsiveness is protonation/deprotonation caused 
by charge distribution over ionizable functional groups 
such as carboxyl or amino groups [46] listed in Table 2. 
Polymers that contain carboxylic, sulfonic acid or amino 
Fig. 3 Environmental regulator of virulent factors matched with 
stimuli classification. A schematic diagram of virulent factors that 
microbes possess which can be regulated by environmental signals 
which can be classified as chemical, biological, or physical
Table 2 pH‑responsive functionalities
Name Structure pH Range References





Methyl maleate 5.5, 6.8 [48]




Acetyl 6–7 [46, 94]
Histidine [48]
Phthalyl [46]
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groups such as poly(l-histidine), poly(methacrylic acid) 
(PMAA),and poly(acrylic acid) (PAA) [48], have been 
commonly used for their pH-responsive functionalities. 
pH changes induce a phase transition in pH-responsive 
polymers very abruptly, which can aid within intracel-
lular compartments or with rapid release of drug cargos 
[46, 48].
3.2  Temperature‑responsive
Changes in an organism’s temperature have been corre-
lated with dramatic changes in the expression of virulent 
factors. Additionally, multitudes of diseases have been 
known to manifest temperature changes [44, 45]. For 
example, Salmonella typhimurium, Bordetella pertus-
sis, Escherichia coli, Vibrio cholera, and Shigella sp. have 
been shown to rely on temperature dependent environ-
mental signals [44]. Normally, a temperature-dependent 
response is characterized by a critical solution tempera-
ture where the hydrophobic and hydrophilic interac-
tions abruptly change within a small temperature range 
[45, 49]. This change induces the disruption of intra- and 
intermolecular electrostatic and hydrophobic interac-
tions and results in collapse or expansion (a volume 
phase transition) [45, 47, 50]. Materials containing this 
group either become insoluble upon heating, classed as 
lower critical solution temperature (LCST), or become 
soluble upon heating, classed as upper critical solu-
tion temperature (UCST) [50]. LCST materials, Table 3, 
are usually based on N-isopropylacrylamide (NIPAM), 
N-vinylcaprolactam (NVCl), methylvinylether (MVE) 
[45, 47, 50–52]. Whereas typical UCST systems are based 
on a combination of acrylamide (AAm) and acrylic acid 
(AAc) [47, 50].
3.3  Light‑ and redox‑responsive
While light might not be an environment dependent 
stimulus, it is an excellent external stimulus that can be 
applied to antimicrobial therapy. By combining UV expo-
sure and drug release, light-responsive systems become 
very advantageous, particularly for antimicrobial systems 
because light can be applied instantaneously and under 
specific conditions with high accuracy [45, 48]. The wave-
length of the light producing laser is tuned to near-infra-
red which is less harmful and has deeper penetration in 
tissues than visible light. Most photo-responsive materi-
als possess light-sensitive functionalities, Table 3, such as 
azobenzene, spiropyran or nitrobenzyl groups [51, 52]. 
Examples of light-responsive antimicrobials can be seen 
in studies using modified TiO2 as a photocatalyst against 
such pathogens as E. coli [53, 54]. Additionally, the use of 
azobenzene- based antimicrobial compound has aided in 
the creation of polymer films active against S. aureus and 
C. albicans [55].
When trying to add redox-response functionality, 
researchers have typically focused on disulfide groups 
as these are unstable in a reducing environment [46, 48, 
51, 56]. There is a redox potential (~100–1000 fold) that 
exists between extracellular and intracellular environ-
ments. The extracellular space environment is oxida-
tive while intracellular is reductive due to glutathione 
concentration. Disulfide links degrade when exposed 
to glutathione or cysteine [52]. This degradation allows 
researchers to tune for environmental signals. At times, 
the redox reaction will alter the hydrophobic and the 
hydrophilic properties of a molecule, leading to a respon-
sive swelling and de-swelling [51, 52] which is another 
responsive that can be taken advantage of for a nAbts 
therapy.
3.4  Enzyme‑responsive
All organisms create special enzymes to help them thrive 
in their microenvironments. For example, bacteria in the 
colon produce reductive enzymes or hydrolytic enzymes 
capable of degrading various types of polysaccharides 
[57]. Researchers can take advantage of this particu-
lar characteristic since most infection sites will over-
express a certain enzyme, and responsive functionality 
can be applied to the material of interest [44]. Usually, in 
enzyme-responsive systems, enzymes are used to destroy 
the polymer or its assemblies [57]. Enzyme-responsive 
systems have many advantages, the largest being that 
they do not require an external trigger for their decom-
position, Table  4. They also exhibit high selectivity and 
work under mild conditions [57]. For example, designing 
linkers that are responsive to pyroglutamyl-peptidase I 
[58, 59], a protease found in S. aureus, can allow for the 
creation of a nAbts that would selectively release at that 
infection site. The major drawback of enzyme-responsive 
systems, however, is the difficulty in establishing a pre-
cise initial response time [57].
Applying stimuli-responsive functionalities to the 
design of nAbts opens up the possibility of creating a mul-
tipurpose antimicrobial with an environmental dependent 
release. Additionally, the opportunity to include a targeted 
drug release functionality is presented. Thus, there is a 
synergist circumstance where the drug can find renewed 
efficacy against a drug-resistant organism.
3.5  Combination of drug molecule with nanoantibiotics
While nAbts alone exhibit excellent antimicrobial prop-
erties, an even more effective therapy can be engineered 
by combining the properties of nAbts with that of con-
ventional antibiotics. nAbts can target one mechanism of 
a microbe whereas conventional antibiotics can be used 
to address another, thus creating a combinatory thera-
peutic system that can tune to a number of scenarios. 
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For example, it has been shown that there is a coopera-
tive antimicrobial effect occurs when chitosan is com-
bined with sulfamethoxazole to combat drug-resistant 
Pseudomonas aeruginosa [60]. Additionally, chitosan-
capped gold nanoparticles coupled with ampicillin pre-
sented a twofold increase in efficacy [61]. A similar trend 
is observed when various aminoglycosides (streptomycin, 
gentamycin, neomycin) were conjugated to gold NPs [62]. 
Silver NPs has also been shown to significantly increase 
the antibacterial activities of drugs such as ampicillin, 
kanamycin, erythromycin, and chloramphenicol when 
tested against E. coli, S. typi, S. aureus, and M. luteus 
[63]. The clinical potential for such combinatory uses of 
nAbts and small drug molecules against drug-resistant 
infections, can also be aided by the addition of a stimuli-
responsive linker, this is exemplified by the improved effi-
cacy found in such attempts [4, 26, 35, 40, 64].
3.6  Nanoparticles with multi‑stimuli response
Another advantageous nAbts design is one that places 
various stimuli into one package. These will require the 
use of different stimuli-responsive linkers with two or 
more nAbts. For instance, a thermo-responsive group 
like NIPAM is combined with pH-responsive function-
ality for the purpose of designing a multi-environment 
NP [47]. These could be very useful in topical applica-
tions where one release will happen at body tempera-
ture, followed by another stimulus-triggered release 
intracellularly or at an inflammatory site. Moreover, a 
multi-stimuli nAbts can be advantageous for treating dif-
ficult intracellular drug-resistant microbe as illustrated in 
Fig. 4. Adding a stimuli-responsive functional group to a 
nAbts such as a gold nanoparticle or a carbon nanotube 
can be accomplished by different methods from surface 
coating using emulsion to reduction-driven synthesis [63, 
65]. For polymeric systems, the method that dictates the 
addition of stimuli-responsive functional group is deter-
mined by the specific group being conjugated. For an 
example, conjugating a pH responsive functionality such 
as succinyl or acetyl to chitosan has been done by various 
groups with relative ease [66–68]. An alternative pairing 
is one that places a light-responsive nanoparticle with 
Table 3 Functionalities responsive to temperature, redox, light, and hypoxia
Name Structure Trigger References
Ethoxyethyl glycidal ether Heat: Δ @ 29.6–40.4 °C [50]
NIPAM–acrylamide Heat: Δ @ 30–32 °C [47, 48, 50]
Methylvinylether Heat: Δ @ 35–37 °C [47, 50]
2-(2-ethoxy) ethoxyethyl vinyl ether Heat: Δ @ 41 °C [50]
Disulfide Glutathione reduction [49, 52, 56]
2-Nitrophenyl ester Ultraviolet light >310 nm [45, 51, 52]
Spiropyran Light [51, 52]
Azobenzene Hypoxia and light [45, 48, 51, 52]
Nitroaromatic Hypoxia [95]
Quinone [45]
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one that has a different antimicrobial mechanism. For 
example, doping TiO2 with silver creates a particle that 
can destroy bacteria by photocatalytic inactivation and 
generation of silver ions [36, 69, 70]. These particles have 
been shown to have excellent light-independent anti-
microbial activities against E. coli, S. aureus and P. aer-
uginosa [69]. A similar interaction can be observed when 
gold is combined with TiO2 NPs. While not necessarily 
used for antimicrobial therapy yet, various groups in the 
cancer research field are already applying the strategy of 
multi-stimuli-responsive particles [71].
4  Challenges for nanoantibiotics
With all the promise of nAbts comes challenges that 
must be addressed before widespread clinical use can 
be adopted. The two main challenges of nanomaterials 
in biological applications are toxicity of the material and 
large scale manufacturing of those materials.
4.1  Toxicity
Various nAbts, particularly metallic and carbon-based 
ones, have severe toxicity generated from prolonged expo-
sure. Although silver NPs provide many benefits, pro-
longed exposure to soluble silver-containing compounds 
may produce an irreversible pigmentation in the skin 
(argyria) and the eyes (argyrosis) in addition to other toxic 
effects [10]. Some studies provide a direct contradiction 
to this, claiming minimal concentration dependent toxic 
effects [10, 72]. These concentration dependent toxici-
ties to mammalian cells have been shown in other studies 
using metallic nanoparticles [73, 74]. Similarly, while nano-
tubes and fullerenes have been shown to be potentially 
toxic, there are some contradictions which suggest that the 
toxicity may be due to solvent contaminants during prepa-
ration [39, 75]. For one, a suspension of nC60 prepared 
without THF lacked toxicity [76]. Moreover, nC60 prepared 
without using any polar organic solvent lacked any acute 
or subacute toxicity in rodents [77]. And although these 
potential side-effects limit their applications, their use 
should not be disregarded entirely. A complete elucida-
tion of nanoparticle toxicity needs to be ascertained before 
extensive manufacturing induced exposure.
In general, there has been increased scrutiny over the 
toxicity of nanoparticles due to increased use in various 
industries. Not only in the application, but also in the 
manufacturing of nanoparticles as those who manufac-
ture the nanoparticles will experience the most exposure. 
Silver NPs have been analyzed to determine their toxic-
ity when manufactured. Based on a continuous 3-day 
exposure assessment, it was evident that workers were 
exposed to high levels of nanoparticles on a day-to-day 
basis; similar results were also found for other metal-
lic and carbon NP manufacturing [78]. While the exact 
toxicities of long-term overexposure are still completely 
unknown, a recent study by Das et  al. [79] looks at the 
potential toxicity to mammalian germ cells and devel-
oping embryos from engineering nanoparticles such as 
gold, silver, fullerenes, and chitosan. They summarize 
various toxicities based on nanoparticle uptake and inter-
nalization mechanisms. The major emphasis of the study 
is that while some nanoparticles may not have any acute 
toxicity, there is a possibility that there is some long-term 
toxicity or effect to germ lines to consider. The authors 
disclose that a large percentage of these toxicities are 
mostly dependent on NP size and surface modifications. 
Taking those variables into consideration when designing 
and engineering nAbts can aid in ameliorating the pos-
sible toxicities that may arise.
4.2  Large‑scale manufacturing
Scale-up for creating nanoparticles requires sophisti-
cated techniques [80]. Two key pathways to generate 
Table 4 Enzyme‑responsive functionalities
Type Example Activity Current application References
Proteases Pyroglutamyl-peptidase I  
(Staphylococcus aureus)
Cytosolic hydrolysis of terminal 
amino groups
Diagnosis, protein sequence analysis, 
antibody target
[58, 59, 99–80]
Lipases PAL (Pseudomonas aeruginosa) Hydrolysis of glycerol esters Synthesis of industrial compounds [100, 101]
Glycosidases EndoS (Streptococcus pyogenes) Modulating the IgG effector func-
tions
Immunomodulation, glycan analysis [102–104]
Urease UreA, UreB (Helicobacter pylori) Conversion of urea to ammonia, 
neutralization of pH
Taxonomic identification, vaccine 
candidate
[105–107]
Glucose oxidase GOx Catalysis of glucose oxidation Food processing, antibacterial, 
antifungal
[108–111]
Peroxidase KatG (Mycobacterium tuberculosis) Activates isoniazid, a frontline anti-TB 
drug
Proteomics, diagnostics [112–116]
Esterase ADP1 (Acinetobacter sp.) Carbamate and ester cleavage Drug abuse treatment, biocatalysis [117, 118]
Amidase AmpD (Citrobacter freundii) Amide cleavage, cell wall recycling Diagnostics [119–121]
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nanoparticles are through chemical or mechanical routes 
[37]; these can also be considered as bottom-up or top-
down manufacturing approaches respectively, Fig.  5 
[81]. A bulk material may be dissolved chemically into 
molecular entities to yield a distinct molecular inter-
mediate form of the material. That intermediate is then 
reacted kinetically or processed further through the use 
of stabilizing agents such as emulsifiers. Generation of 
silver nanoparticles from silver nitrate is an excellent 
example of a chemical route [37]. Alternatively, mechani-
cal energy can also be applied to a bulk material to split 
it into smaller particles. This usually requires heavy 
machinery such as a mill. Regardless of the chosen path-
way, most particles are modified, whether by some type 
Fig. 4 a Formation of a stimuli-responsive nanoantibiotics particle: a combined system can be created by combining conventional antibiotics 
with nanoantibiotics. Stimuli response can aid in the synergistic efficacy by allowing a particle to display multiple therapeutic effect based on the 
stimulus applied. b Proposed therapeutic effect of stimuli-responsive nanoantibiotics against intracellular infection. To target intracellular microbes, 
conventional antibiotics are combined with nanoantibiotics with stimuli response. Upon endocytosis, these stimuli-responsive nanoantibiotics (sr-
nAbts) are triggered to release after certain environmental triggers. With pH triggered release, the particle unpacks to escape the endosome, target 
the microbe with 1 drug and nAbts. Based on the infection, a second trigger can release another drug and use an additional nAbts mechanism
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of surface modification or another type of customization, 
before further use [37].
Another method used to industrially generate nano-
particles is an emulsion type system [82, 83]. This is a 
bottom-up synthesis approach that has some similarity 
to chemical synthesis route. Instead of distinct interme-
diates being formed, the emulsion route allows for the 
formation of nanoparticles based on an oil–water sys-
tem. The versatility of the reactor system, where starting 
materials may simply be mixed, serves as an advantage 
for this system. A disadvantage of the emulsion system 
is that it will be limited to only certain types of nanopar-
ticles made with materials that are soluble in an organic 
phase or an aqueous layer, and thus, it cannot be widely 
used.
The other end of the spectrum for scaling and manufac-
turing is the top-down approach of templated systems [84, 
85]. Using cast molding generated from polydimethylsi-
loxane (PDMS), different shapes and sizes can be gener-
ated for a material that can be cured and dried, usually a 
polymeric material. While most nAbts are not applicable 
to this technique, there might be a way of combining the 
stimuli-responsive linkers or polymers that will allow for 
the templated-assisted system to be leveraged. The main 
advantage of using a template-like system is the ability to 
make many uniform nanoparticles very rapidly. This would 
reduce the cost of manufacturing for pharmaceutical appli-
cations while being able to maintain consistent quality. This 
consistency is something that the bottom-up approach may 
lose. The downside is the limited source materials that can 
be used in the template-assisted systems.
One thing is certain, when industrial scale manufac-
turing of nAbts comes into question, attempting to use 
just one system may not be adequate enough to serve a 
broad therapeutic need. Entities that decide to venture 
into commercializing nAbts for therapeutic applications 
need to consider which systems they are trying to target, 
and what would be the safest and most economical way 
to accomplish that goal.
5  Future directions for nanoantibiotics
Worldwide, scientists are scrambling to discover and 
uncover new ways to fight off infections. The rate of 
drug-resistant formation is frightening, and while there 
are many promising new compounds and products being 
introduced, unfortunately, that is still not enough. The 
major problem lies in the fact that we are stalled in this 
persistent paradigm of discovering new antibiotics. Of the 
few pharmaceutical companies that invest money into the 
discovery of new antibiotics, most do not see a return on 
their investment. This makes the prospect of developing 
new antibiotic highly unattractive from that standpoint.
However, the difficulty in developing new antibiotic 
compounds stems from the fact that most new antibiotic 
compounds are found from another, competing microbe 
[12, 86]. nAbts circumvent that system by using a com-
pletely different mechanism of action; moreover, they 
are also highly versatile and tunable. This allows for the 
Fig. 5 Manufacturing methods of nanoparticle. Nanoparticles can be manufactured in large scales either by bottom-up or top-down manufactur-
ing methods
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ubiquitous use of nAbts. Antimicrobials are used in a 
multitude of industries such as livestock and agriculture, 
water treatment, military, and clinics; however, sr-nAbts 
will most likely thrive in industries that require the pre-
cise release of certain antibiotic effect after certain condi-
tions are met. One possible application is to apply it to 
on-site or field-based medical devices, where autoclave 
or sterilization is not easily accessible. This will allow for 
situations where temperature, light, or pH responsive 
nAbts coated materials can react to sterilize an environ-
ment. The same system can also be used in the design of 
a water treatment system where the filter self-cleans and 
sterilizes itself. Another possible direction would be a 
theranostic system for antimicrobial infections. This is 
a relatively direct venture if the nAbts system is stimuli-
responsive. The timing of such a system would be most 
useful in topical applications, or applications where an 
infection status may be uncertain. These types of nAbts 
theranostic system could also be very useful in curbing 
the spread of sexually transmitted infections, such as 
Neisseria gonorrhea, by applying them to contraceptives. 
Bacteriophages, though excluded can be classified as bio-
active nanoantibiotics. These phages are virus-like parti-
cles that selectively kill bacteria when they infect them, 
without any damage to the eukaryotic cell [87]. Further-
more, phages can be modified with stimuli-responsive 
functionalities that allow for added efficacy and capa-
bilities [88]. Additionally, non-lytic phages can be engi-
neered to permit use as vaccines or diagnostic tools 
against specific bacterial infections [89].
It is important to note, fortunately, that the antibiotic 
industry is gaining some steam. Aside from the obvious 
need, this renewed interest in antimicrobial discovery 
is likely due to the expected increase in the value of the 
industry. BCC Research reports the market to be worth 
about 40.6 billion in 2015 with an expected compound 
annual growth rate of 2.0 % within the next 5 years [90, 
91]. Regardless of the source, whether it is IBIS World 
Industry Report, Statista, or BCC Research Reports, 
there is a general agreement over the size of the current 
antimicrobial market. However, the forecasted direction 
of the market is still uncertain. This uncertainty might 
be caused by the upcoming patent cliffs, production of 
cheaper generics, or loss of efficacy due to drug-resistance 
formation. Irrespective of that, about 3.7 % of the over 1 
trillion-dollar pharmaceuticals industry [90] is focused on 
antibiotics, Fig. 6. While it maybe not be the largest sec-
tor, it has been drawing increased interest. Interestingly 
enough, the number of clinical devices focusing on some 
sort of nAbts application that has received approval for 
use continues to increase, Table 5 [3].
6  Conclusions
There is a lot of promise to be found in the field of anti-
microbial therapy using nanoparticles. It is an auspicious 
field that might provide long-term solutions to the for-
mation antimicrobial resistance. One of the major advan-
tages provided by the use of the sr-nAbts system is that 
it allows for the bypass of traditionally antibiotic discov-
ery pathways. The mechanism of action is not something 
that is already found in microbial architecture, which 
might cause a longer time for resistances to form. And 
although rapid progress is being made, there are still 
some topics of concern with respect to toxicity, especially 
to those that will manufacture the materials. With those 
addressed, the therapeutic possibilities are endless.
Fig. 6 Antibiotics market share in comparison to the overall pharmaceutical market size. Antibiotics account for 4 % of the total market which is 
equal to or larger than some of the other markets, and has a potential for growth
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